Tags

Type your tag names separated by a space and hit enter

Axial spondyloarthritis.
Nat Rev Dis Primers 2015; 1:15013NR

Abstract

The term axial spondyloarthritis covers both non-radiographic disease and radiographic disease (also known as ankylosing spondylitis). Some studies have been performed to investigate the prevalence of axial spondyloarthritis, although most are limited to patients with radiographic disease. A strong genetic association has been shown between axial spondyloarthritis and human leukocyte antigen-B27 (HLA-B27), but the pathogenetic role of HLA-B27 has not yet been clarified. Tumour necrosis factor (TNF), IL-17, IL-23 and downstream pathways also seem to be important - based on the good results of therapies directed against these molecules - but their exact role in the inflammatory process is also not yet clear. Elucidating the interaction between osteoproliferation and inflammation will be crucial for the prevention of long-term structural damage of the bone. The development of new criteria for classification, diagnosis and screening of patients with axial spondyloarthritis will enable earlier intervention for this chronic inflammatory disease. MRI has become an important tool for the early detection of axial spondyloarthritis. NSAIDs and TNF blockers are effective therapies, including in the early non-radiographic stage. Therapeutic blockade of IL-17 or IL-23 seems to be a promising new treatment option. Tools for measuring quality of life in axial spondyloarthritis have become relevant to assess the impact that the disease has on patients. These diagnostic and therapeutic advances will continue to change the management of axial spondyloarthritis, and new insights into the disease pathogenesis will hopefully accelerate this process. For an illustrated summary of this Primer, visit: http://go.nature.com/51b1af.

Authors+Show Affiliations

Rheumatology, Charité, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany.Rheumazentrum Ruhrgebiet, Herne, Germany.Faculty of Medicine, Paris Descartes University, Department of Rheumatology, Hôpital Cochin, Assistance Publique, Hôpitaux de Paris, INSERM (U1153), Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France.Clinical Immunology and Rheumatology and Amsterdam Rheumatology and Immunology Center, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27188328

Citation

Sieper, Joachim, et al. "Axial Spondyloarthritis." Nature Reviews. Disease Primers, vol. 1, 2015, p. 15013.
Sieper J, Braun J, Dougados M, et al. Axial spondyloarthritis. Nat Rev Dis Primers. 2015;1:15013.
Sieper, J., Braun, J., Dougados, M., & Baeten, D. (2015). Axial spondyloarthritis. Nature Reviews. Disease Primers, 1, p. 15013. doi:10.1038/nrdp.2015.13.
Sieper J, et al. Axial Spondyloarthritis. Nat Rev Dis Primers. 2015 07 9;1:15013. PubMed PMID: 27188328.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Axial spondyloarthritis. AU - Sieper,Joachim, AU - Braun,Jürgen, AU - Dougados,Maxime, AU - Baeten,Dominique, Y1 - 2015/07/09/ PY - 2016/5/19/entrez PY - 2015/1/1/pubmed PY - 2015/1/1/medline SP - 15013 EP - 15013 JF - Nature reviews. Disease primers JO - Nat Rev Dis Primers VL - 1 N2 - The term axial spondyloarthritis covers both non-radiographic disease and radiographic disease (also known as ankylosing spondylitis). Some studies have been performed to investigate the prevalence of axial spondyloarthritis, although most are limited to patients with radiographic disease. A strong genetic association has been shown between axial spondyloarthritis and human leukocyte antigen-B27 (HLA-B27), but the pathogenetic role of HLA-B27 has not yet been clarified. Tumour necrosis factor (TNF), IL-17, IL-23 and downstream pathways also seem to be important - based on the good results of therapies directed against these molecules - but their exact role in the inflammatory process is also not yet clear. Elucidating the interaction between osteoproliferation and inflammation will be crucial for the prevention of long-term structural damage of the bone. The development of new criteria for classification, diagnosis and screening of patients with axial spondyloarthritis will enable earlier intervention for this chronic inflammatory disease. MRI has become an important tool for the early detection of axial spondyloarthritis. NSAIDs and TNF blockers are effective therapies, including in the early non-radiographic stage. Therapeutic blockade of IL-17 or IL-23 seems to be a promising new treatment option. Tools for measuring quality of life in axial spondyloarthritis have become relevant to assess the impact that the disease has on patients. These diagnostic and therapeutic advances will continue to change the management of axial spondyloarthritis, and new insights into the disease pathogenesis will hopefully accelerate this process. For an illustrated summary of this Primer, visit: http://go.nature.com/51b1af. SN - 2056-676X UR - https://www.unboundmedicine.com/medline/citation/27188328/Axial_spondyloarthritis_ L2 - http://dx.doi.org/10.1038/nrdp.2015.13 DB - PRIME DP - Unbound Medicine ER -